BioStock: New promising data from Scandion Oncology’s cancer study

At the end of last week, Scandion Oncology reported phase II data from the first cohort of chemotherapy-resistant colorectal cancer patients treated with the company’s drug candidate SCO-101 in combination with the standard chemotherapy FOLFIRI. The results are encouraging for the further development of the candidate.

Read the full article about Scandion Oncology at biostock.se:

https://www.biostock.se/en/new-promising-data-from-scandion-oncologys-cancer-study/

This is a press release from BioStock - Connecting Innovation & Capitalhttps://www.biostock.se/

About Us

Scandion Oncology A/S is a biotechnology company founded in 2017 for the purpose of addressing one of the most important challenges in modern oncology – the effective treatment of cancer which contains drug resistant cell clones or which has developed resistance to a previously prescribed cancer drug. The Company’s leading candidate drug, SCO-101, is now ready for phase II testing in patients with drug resistant cancer disease.

Subscribe

Quick facts

BioStock: New promising data from Scandion Oncology’s cancer study
Tweet this